MedTrace Logo

Randomized Placebo-controlled Study of ISA247 in Plaque Psoriasis

NCT00244842 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 451

Last updated 2023-03-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine which dose of voclosporin is effective in the treatment of plaque psoriasis compared to placebo.

Conditions

Interventions

DRUG

voclosporin

voclosporin 0.2, 0.3, or 0.4 mg/kg po BID

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Aurinia Pharmaceuticals Inc.

    lead INDUSTRY

Principal Investigators

  • Robert Bissonnette, MD · Innovaderm Research

  • Richard Langley, MD, FRCPC · Eastern Canada Cutaneous Research Associates Ltd.

  • Gilles Lauzon, PhD MD FRCPC · Western Canada Dermatology Institute

  • Kim Papp, MD, PhD · Probity Medical Research

  • Neil Shear, MD · Ventana Clinical Research Organization

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2005-10-31
Completion
2005-10-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00244842 on ClinicalTrials.gov